Company profile
Celularity Inc
NASDAQ:CELUBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Taniraleucel | phase1 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02552277 | phase2 | completed | 2015-10-27 | 2017-03-07 | Celularity Incorporated | A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy |
| NCT01769755 | phase1 | completed | 2013-03-01 | 2014-11-01 | Celularity Incorporated | A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease |
| NCT02781467 | phase1 | terminated | 2016-07-11 | 2017-12-07 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) |
| NCT02955550 | phase1 | completed | 2017-01-05 | 2018-07-10 | Celularity Incorporated | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) |
| NCT05218408 | phase1_2 | withdrawn | 2021-09-01 | 2021-10-23 | Celularity Incorporated | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type |
FDA applications (0)
No records yet.